Mode
Text Size
Log in / Sign up

Radiation therapy and nasopharyngeal cancer significantly increase risk of chronic rhinosinusitis in head and neck cancer patientsHead and neck cancer treatments may increase risk of sinus issues

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that radiation therapy and nasopharyngeal cancer significantly increase the risk of chronic rhinosinusitis.

This meta-analysis evaluates the incidence and risk factors of chronic rhinosinusitis (CRS) in 3685 adult patients with head and neck cancers. The study identifies an overall pooled incidence of CRS of 0.37 (95% CI, 0.27-0.47). Specific subsets showed higher risks: patients with nasopharyngeal cancer (NPC) had a higher incidence of 0.45 compared to 0.18 in other patients (p < 0.001).

Regarding risk factors, radiation therapy was associated with a higher risk of CRS (log OR = 1.46; 95% CI, 0.76, 2.16). This risk was even more pronounced in patients with NPC (log OR of 1.82 vs. log OR of 0.52; p = 0.01). Additionally, concurrent chemotherapy and advanced disease stages were associated with an increased risk of CRS. Maxillary sinus involvement was the most common site of involvement (0.60).

Limitations include significant heterogeneity in how CRS was diagnosed across the included studies. Clinicians should consider these risk factors, particularly for patients with NPC or those undergoing radiation therapy, when managing head and neck cancers. The findings suggest that these patients may require closer monitoring for sinus complications.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the specific risk factors for chronic rhinosinusitis in head and neck cancer patients. While previous evidence noted that egg consumption is associated with higher head and neck cancer risk, this study specifically identifies radiation therapy and nasopharyngeal cancer as significant drivers for subsequent chronic rhinosinusitis. It also identifies advanced disease stage as a risk factor for CRS, providing more specific clinical indicators for monitoring complications in this patient population.

Living with head and neck cancer is a heavy burden, and the treatments used to fight the disease can sometimes lead to lasting complications. New data shows that many of these patients also develop chronic rhinosinusitis, which is a long-term inflammation of the sinuses. This condition is particularly common in patients with nasopharyngeal cancer, where the risk is significantly higher than in other types of head and neck cancers.

Researchers looked at data from over 3,600 patients to see what factors increase the risk of these sinus problems. They found that radiation therapy is a major factor. Patients who received radiation were more likely to develop chronic rhinosinusitis. This risk was even more pronounced for those with nasopharyngeal cancer who underwent radiation. Other factors like advanced disease stages and the use of chemotherapy alongside radiation also showed a link to higher risks.

While these findings help doctors better prepare for potential complications, there is a note of caution. Because different doctors used different ways to diagnose the sinus issues, the results can vary. However, the data clearly shows that patients with advanced disease or specific types of cancer need extra attention regarding their sinus health during and after treatment.

What this means for you:
Radiation and advanced cancer stages increase the risk of chronic sinus inflammation in head and neck cancer patients.

Common questions

What is the risk of developing sinus issues after cancer treatment?

About 37% of all patients with head and neck cancers develop chronic rhinosinusitis. This risk is even higher for those with nasopharyngeal cancer, where the rate is 45%.

Does radiation therapy increase the risk of sinus problems?

Yes, radiation therapy is linked to a higher risk of chronic rhinosinusitis. This risk is especially high for patients with nasopharyngeal cancer who receive radiation.

Which parts of the sinuses are most commonly affected?

The maxillary sinus is the most common site of involvement, affecting 60% of cases. The ethmoid sinus is also commonly involved, occurring in 45% of cases.

Study Details

Study typeMeta analysis
Sample sizen = 3,685
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
OBJECTIVE: Several studies have described the occurrence of chronic rhinosinusitis (CRS) in adult patients with head and neck cancers (HNC). The goal of this review is to identify the incidence and risk factors for CRS in adult patients with HNC. DATA SOURCES: PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials. REVIEW METHODS: A systematic search was performed from inception to July 2025 and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. Studies that looked at the development of CRS following treatment of HNC were included. RESULTS: Seventeen studies representing a total of 3685 patients were pooled. There was significant heterogeneity in how CRS was diagnosed. The overall pooled incidence of CRS in all HNC patients was 0.37 (95% CI, 0.27-0.47). The incidence was significantly higher in patients with nasopharyngeal cancer (NPC) (0.45 vs. 0.18, p < 0.001). The maxillary sinuses were the most common sinuses involved with an incidence of 0.60 followed by the ethmoid sinuses at 0.45. Radiation therapy was associated with a higher risk of CRS (log OR = 1.46, 95% CI of 0.76, 2.16), especially in patients with NPC (log OR of 1.82 vs. log OR of 0.52, p = 0.01). Qualitative review showed that concurrent chemotherapy and advanced disease stage also increased the risk of CRS. CONCLUSIONS: The presence of NPC, radiation therapy, advanced stage, and concurrent chemotherapy significantly increases the risk of CRS in patients with head and neck cancers. Clinicians should be aware of the risk when treating these patients.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.